Update on allergic rhinitis.
AR is an increasingly common inflammatory disorder. In patients with AR, abnormalities in the immune response trigger inflammatory reactions to otherwise innocuous substances, such as pollen, mold, and house dust mites. An array of environmental and pharmacologic options for AR is available, which should be tailored to the patient's symptoms and lifestyle. Investigational immunotherapies may prove valuable for patients who have an inadequate response to current therapies or experience intolerable adverse events.
Delafuente
Jeffrey C
JC
Geriatric Programs, Virginia Commonwealth University School of Pharmacy, Richmond, USA.
Cheigh
Nina Han
NH
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D000069444:Omalizumab; D010593:Pharmaceutical Services; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology
D000305:Adrenal Cortex Hormones; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D006634:Histamine H1 Antagonists; D000069444:Omalizumab